In Response to Comment on "Safety of Physostigmine for Pediatric Antimuscarinic Poisoning".

Autor: Nañagas K; Indiana University School of Medicine, Indianapolis, IN, USA. knanagas@iuhealth.org.; IU Health Methodist Hospital, 1701 North Senate Blvd. B412b, Indianapolis, IN, 46234, USA. knanagas@iuhealth.org.; Indiana University Health- Academic Health Center, Indianapolis, IN, USA. knanagas@iuhealth.org.; Indiana Poison Center, Indianapolis, IN, USA. knanagas@iuhealth.org., Huber S; Indiana University School of Medicine, Indianapolis, IN, USA.; IU Health Methodist Hospital, 1701 North Senate Blvd. B412b, Indianapolis, IN, 46234, USA., Avera R; Indiana University School of Medicine, Indianapolis, IN, USA.; IU Health Methodist Hospital, 1701 North Senate Blvd. B412b, Indianapolis, IN, 46234, USA.; Indiana University Health- Academic Health Center, Indianapolis, IN, USA.; Indiana Poison Center, Indianapolis, IN, USA., Penfound S; IU Health Methodist Hospital, 1701 North Senate Blvd. B412b, Indianapolis, IN, 46234, USA.; Indiana Poison Center, Indianapolis, IN, USA., Overberg A; Indiana University School of Medicine, Indianapolis, IN, USA.; IU Health Methodist Hospital, 1701 North Senate Blvd. B412b, Indianapolis, IN, 46234, USA.; Indiana University Health- Academic Health Center, Indianapolis, IN, USA.; Indiana Poison Center, Indianapolis, IN, USA.
Jazyk: angličtina
Zdroj: Journal of medical toxicology : official journal of the American College of Medical Toxicology [J Med Toxicol] 2024 Oct; Vol. 20 (4), pp. 440. Date of Electronic Publication: 2024 Jul 31.
DOI: 10.1007/s13181-024-01023-y
Databáze: MEDLINE